NVAX(Novavax, Inc.) · 财务报表

NVAX(Novavax, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$1.15B$1.98B$983.71M$682.16M$1.12B
毛利润$1.15B$1.08B$639.94M$479.42M$1.05B
营业利润−$1.69B−$644.74M−$566.51M−$248.93M$452.80M
净利润−$1.74B−$657.94M−$545.06M−$187.50M$440.30M
经营现金流$322.95M−$415.94M−$713.97M−$87.26M−$244.63M
自由现金流$265.46M−$504.99M−$767.74M−$100.32M−$250.19M
摊薄每股收益$-23.44$-8.42$-5.41$-1.23$2.58

Novavax, Inc. NVAX